Advanced search
Publication Cover
Renal Failure Volume 46, 2024 - Issue 1
Submit an article Journal homepage
363
Views
0
CrossRef citations to date
0
Altmetric
Anemia and Hematologic Disorders

Hemoglobin level and erythropoietin response in hemodialysis patients: what can we pay attention to?

Yu Zhaoa Department of Medicine, Northwest Minzu University, Lanzhou, PR China;b Department of the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR ChinaView further author information
,
Kun Zhaob Department of the Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, PR ChinaView further author information
,
Jingchen Fanga Department of Medicine, Northwest Minzu University, Lanzhou, PR ChinaView further author information
&
Wenyun Wangc Department of Pediatric Surgery, the Second Hospital of Lanzhou University, Lanzhou, PR ChinaCorrespondence[email protected]
View further author information
Article: 2353338 | Received 22 Apr 2024, Accepted 03 May 2024, Published online: 13 May 2024

References

  • Cui L, Zhang L, Li J, et al. Correlation between ultrafiltration rate and hemoglobin level and erythropoietin response in hemodialysis patients. Ren Fail. 2024;46(1):2296609. doi:10.1080/0886022X.2023.2296609.
  • Zhan Y, Chen R, Zheng W, et al. Association between serum magnesium and anemia: China health and nutrition survey. Biol Trace Elem Res. 2014;159(1-3):39–45. doi:10.1007/s12011-014-9967-x.
  • Biyik Z, Yavuz YC, Altintepe L. Association between serum magnesium and anemia in patients with chronic kidney disease. Int Urol Nephrol. 2020;52(10):1935–1941. doi:10.1007/s11255-020-02525-8.
  • Yu L, Song J, Lu X, et al. Association between serum magnesium and erythropoietin responsiveness in hemodialysis patients: a cross-sectional study. Kidney Blood Press Res. 2019;44(3):354–361. doi:10.1159/000500921.
  • Pethő ÁG, Tapolyai M, Browne M, et al. Hypomagnesemia as a risk factor and accelerator for vascular aging in diabetes mellitus and chronic kidney disease. Metabolites. 2023;13(2):306. doi:10.3390/metabo13020306.
  • Ingrasciotta Y, Lacava V, Marcianò I, et al. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol. 2019;20(1):359. doi:10.1186/s12882-019-1554-0.
  • Sakaguchi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi:10.1681/ASN.2018101007.
  • Weir MR. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am J Nephrol. 2021;52(6):450–466. doi:10.1159/000516901.
  • National Clinical Research Centre for Kidney Disease. Summary of Chinese guidelines for the diagnosis and treatment of chronic kidney disease mineral and bone abnormalities. J Nephrol Dialy Transplant. 2019;28(1):52–57.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.